EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity

Shulin Hou iD, Yunyun Zhang, Xin Zheng, Ruining Li, Taoran Zhao, Hua Qiao, Xiaozheng Zhang iD, Zhizhen Liu

Viruses · 2025

DOI: 10.3390/v17091167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Shulin Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Key Laboratory of Birth Defect and Cell Regeneration, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Department of Bio…. Hauptthemen laut MEDLINE: Antiviral Agents, Nanoparticles, Angiotensin-Converting Enzyme 2, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanxi Provincial Research Foundation for Basic Research, National Key R&D program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiotensin-converting enzyme 2 (ACE2) is a key mediator of SARS-CoV-2 host cell entry, making it an attractive target for drug delivery strategies. Nafamostat (NM), a multifunctional agent with antiviral and anti-inflammatory properties, holds promise for COVID-19 treatment. In this study, we developed PLGA-PEG nanoparticles encapsulating NM (NM-PP NPs) and further conjugated them with specific ACE2 decoys (CTC-445.2d or SI5α) to generate NM-PP-Pro/Pep NPs. Both unmodified and ACE2-decoy-modified NPs exhibited uniform size distributions (diameter < 200 nm) and negative surface charges, as confirmed by dynamic light scattering and zeta potential measurements. The nanoparticles maintained structural integrity for at least 18 days at 4 °C and room temperature. In vitro release studies revealed sustained and controlled NM release kinetics. Notably, NM-PP-Pro NPs displayed potent antiviral activity, with an IC50 < 0.05 nM against wild-type SARS-CoV-2 and remained effective against the D614G variant (IC50 = 2 nM). These results underscore the potential of NM-PP-Pro NPs as a versatile nanotherapeutic platform for targeting SARS-CoV-2 and its emerging variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsNanoparticlesAngiotensin-Converting Enzyme 2Polyethylene GlycolsCarbamatesGuanidinesSARS-CoV-2BenzamidinesHumansVero CellsAnimalsCOVID-19 Drug TreatmentChlorocebus aethiopsCOVID-19Drug Carriers

Stichwörter der Autor:innen

ACE2 decoyPLGA-PEGSARS-CoV-2nafamostatnanoparticles

Substanzen

Antiviral AgentsAngiotensin-Converting Enzyme 2Polyethylene GlycolsnafamostatBenzamidinesCarbamatesGuanidinesACE2 protein, humanDrug Carriers

Autor:innen und Institutionen

  • Shanxi Key Laboratory of Birth Defect and Cell Regeneration, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Department of Biochemistry and Molecular Biology, College of Basic Medicine, Shanxi Med…
  • Academy of Medical Sciences, Shanxi Medical University, Taiyuan 030001, China.

ORCID-Profile: Shulin Hou, Xiaozheng Zhang

Förderung

  • Shanxi Provincial Research Foundation for Basic Research
  • National Key R&amp;D program

Zitieren

APA

Hou, S., Zhang, Y., Zheng, X., Li, R., Zhao, T., Qiao, H., Zhang, X., & Liu, Z. (2025). ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity. Viruses. https://doi.org/10.3390/v17091167

Vancouver

Hou S, Zhang Y, Zheng X, Li R, Zhao T, Qiao H, et al. ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity. Viruses. 2025. doi:10.3390/v17091167

BibTeX
@article{Hou2025,
  author = {Hou, Shulin and Zhang, Yunyun and Zheng, Xin and Li, Ruining and Zhao, Taoran and Qiao, Hua and Zhang, Xiaozheng and Liu, Zhizhen},
  title = {ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17091167}
}
Kostenlos starten →